On the heels of GW's epilepsy win, Wall Street darling Zogenix shares positive PhIII data on rival drug
A rival is already looming for GW Pharmaceuticals $GWPH, the drugmaker who scored the very first cannabis-derived drug approval only weeks ago to treat rare …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.